Genentech, a member of the Roche Group, today raised the final beam of its new manufacturing facility in Holly Springs, North Carolina, during a topping out ceremony.
The milestone reflects continued on-time progress on Genentech’s approximately $2 billion investment in its first-ever East Coast manufacturing facility. It follows the project’s May 2025 initial investment announcement, August 2025 groundbreaking, and January 2026 expansion announcement.
Once operational, the facility will produce treatments for metabolic conditions, such as obesity. It will incorporate advanced biomanufacturing, automation, robotics and the latest digital manufacturing technologies designed to increase production efficiency, support sustainability, and strengthen Genentech’s U.S.-based supply chain.
The investment in technology includes an advanced digital twin – an AI-powered, data-driven virtual model of the manufacturing facility designed to simulate operations and test scenarios before real-world implementation. The approach improves overall reliability and minimizes waste ultimately helping critical medicines reach people faster.
Expected to support more than 2,000 jobs, including more than 500 high-wage manufacturing roles and more than 1,500 construction jobs, the facility reinforces Holly Springs and the broader Raleigh-Durham region as a growing center for biopharmaceutical manufacturing and innovation. To support this workforce, Genentech is partnering with local academic institutions to prepare talent for manufacturing careers in AI, robotics, automation, and advanced biomanufacturing across operations, maintenance, engineering, labs and warehouses.
The facility is part of Roche and Genentech’s broader $50 billion commitment to R&D and manufacturing infrastructure in the U.S. Roche and Genentech’s current U.S. footprint includes 13 manufacturing sites, 15 research and development sites and approximately 25,000 employees across 24 locations in eight states.
